aibioCABA Cabaletta Bio, Inc.
Cabaletta Bio (CABA) news
Top story · Aug 13, 2026 · SEC filing 8-K
Cabaletta Bio reports results
Latest Cabaletta Bio news
We have not published a story on Cabaletta Bio yet. When there is news, it will appear here.
What Cabaletta Bio does
Cabaletta Bio, Inc. is a late clinical-stage biotechnology company that develops engineered T cell therapies intended to provide deep and durable responses with one-time administration in patients with autoimmune diseases. Its proprietary CABA platform, short for Cabaletta Approach to B cell Ablation, uses the CARTA approach, which stands for Chimeric Antigen Receptor T cells for Autoimmunity. Its lead product candidate, resecabtagene autoleucel (rese-cel), is a 4-1BB co-stimulatory domain-containing, fully human CD19-CAR T construct designed to deplete B cells, with repopulation by healthy transitional and naive B cells. The company initiated a registrational trial of rese-cel in dermatomyositis or anti-synthetase syndrome in December 2025 within its RESET-Myositis program. Its RESET-SLE program covers systemic lupus erythematosus and lupus nephritis, and Phase 1/2 trials also evaluate rese-cel in systemic sclerosis and generalized myasthenia gravis. Partnered Contract and Development Manufacturing Organizations produce the product, and in January 2026 the company announced INDa clearance for manufacturing on the Cellares Cell Shuttle.
| Product or program | What it is | Stage |
|---|---|---|
| rese-cel (resecabtagene autoleucel) | Fully human CD19 CAR T construct for autoimmune diseases | Registrational trial in dermatomyositis or anti-synthetase syndrome |
| RESET-SLE | Rese-cel program in systemic lupus erythematosus and lupus nephritis | Phase 1/2; registrational cohort designs announced January 2026 |
| Rese-cel in systemic sclerosis and generalized myasthenia gravis | Engineered T cell therapy trials in autoimmune conditions | Phase 1/2 |
| Rese-cel without preconditioning | Evaluated in pemphigus vulgaris, non-renal SLE and lupus nephritis | Phase 1/2 in pemphigus vulgaris |
| Rese-cel on Cellares Cell Shuttle | Automated manufacturing platform for rese-cel | INDa clearance announced January 2026 |
Cabaletta Bio annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $142.7 million | $97.2 million |
| Net income (loss) | -$167.9 million | -$115.9 million |
| Cash from operations | -$131.1 million | -$88.2 million |
| Cash and equivalents | $83.0 million | $164.0 million |
| Short-term investments | $50.6 million | $0 |
Questions about Cabaletta Bio
What is the ticker symbol of Cabaletta Bio?
Cabaletta Bio, Inc. trades under the ticker CABA on NASDAQ.
Where is Cabaletta Bio listed?
Cabaletta Bio, Inc. is listed on NASDAQ.
What is the SEC CIK of Cabaletta Bio?
The SEC Central Index Key (CIK) for Cabaletta Bio, Inc. is 1759138. Its filings are on SEC EDGAR.
How many shares does Cabaletta Bio have outstanding?
169,545,445 shares as of 2026-08-07, per the cover page of its 10-Q filed 2026-08-13.
Which country or territory is Cabaletta Bio listed under?
Our directory records Cabaletta Bio, Inc. under United States.
What does Cabaletta Bio do?
Our directory classifies Cabaletta Bio, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
What is the ISIN of Cabaletta Bio?
The ISIN recorded for Cabaletta Bio, Inc. is US12674W1099.
Does aibio.space cover Cabaletta Bio?
aibio.space lists Cabaletta Bio, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Cabaletta Bio incorporated?
SEC records list its state or country of incorporation as DE.
What does Cabaletta Bio develop?
Cabaletta Bio, Inc. is a late clinical-stage biotechnology company that develops engineered T cell therapies intended to provide deep and durable responses with one-time administration in patients with autoimmune diseases. Its proprietary CABA platform, short for Cabaletta Approach to B cell Ablation, uses the CARTA approach, which stands for Chimeric Antigen Receptor T cells for Autoimmunity.
What is rese-cel (resecabtagene autoleucel) from Cabaletta Bio?
rese-cel (resecabtagene autoleucel): Fully human CD19 CAR T construct for autoimmune diseases Stage: Registrational trial in dermatomyositis or anti-synthetase syndrome.
What is RESET-SLE from Cabaletta Bio?
RESET-SLE: Rese-cel program in systemic lupus erythematosus and lupus nephritis Stage: Phase 1/2; registrational cohort designs announced January 2026.
Is Cabaletta Bio profitable?
Cabaletta Bio, Inc. reported a net loss of $167.9 million for the fiscal year ended Dec 31, 2025, and used $131.1 million of cash in operations, per its annual report to the SEC.
How much does Cabaletta Bio spend on research and development?
$142.7 million in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does Cabaletta Bio have?
$225.1 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
Investor discussion: Cabaletta Bio
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
- Financings
Reported a financing. SEC Form 8-K (Items 8.01). Source
- Listings
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.03,5.07,9.01). Source
- Financings
Reported a financing. SEC Form 424B5. Source
- Financings
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
- Distress
Reported the end of a material agreement. SEC Form 8-K (Items 1.02,7.01,8.01,9.01). Source
- Listings
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.03,5.07,9.01). Source
- Distress
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Stock chart
SEC filings and registration
- SEC name
- Cabaletta Bio, Inc.
- CIK
- 1759138
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) (2836)
- US tickers
- CABA (Nasdaq)
- State or country of incorporation
- DE
- Fiscal year ends
- December 31
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Business address
- 2929 ARCH STREET, PHILADELPHIA, PA, 19104
- Phone
- (267) 759-3100
- Shares outstanding
- 169,545,445 as of 2026-08-07 (10-Q filed 2026-08-13)
Recent filings
Listing details
- Company
- Cabaletta Bio, Inc.
- Ticker
- CABA
- Listing
- NASDAQ
- Country or territory
- United States
- Business scope
- Biotechnology
- ISIN
- US12674W1099
- Last quote in directory
- 2026-10-21
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction